title: Comparison of substance use milestones in cannabis- and cocaine-dependent patients.
abstract: OBJECTIVE
  To compare the progression of substance use milestones between cocaine- and cannabis-dependent patients.
  
  
  METHODS
  Using data gathered from two separate clinical studies for treatment of cocaine dependence and cannabis dependence, 130 cannabis-dependent and 112 cocaine-dependent individuals were compared on milestones related to their substance use.
  
  
  RESULTS
  In cannabis- vs. cocaine-dependent patients, the mean age of first use, regular use and first treatment contact differed significantly. No statistically significant differences were found between the two groups for other measured milestones.
  
  
  CONCLUSIONS
  These results differ from most epidemiologic studies that suggest cocaine users progress more rapidly to regular use and treatment contact.
authors.affiliation: Division on Substance Abuse, New York Psychiatric Institute, New York, New York 10022, USA. jth2014@columbia.edu
authors.forename: Jonathan T
authors.initials: JT
authors.lastname: Horey
authors.forename: John J
authors.initials: JJ
authors.lastname: Mariani
authors.forename: Wendy Y
authors.initials: WY
authors.lastname: Cheng
authors.forename: Adam
authors.initials: A
authors.lastname: Bisaga
authors.forename: Maria
authors.initials: M
authors.lastname: Sullivan
authors.forename: Edward
authors.initials: E
authors.lastname: Nunes
authors.forename: Frances R
authors.initials: FR
authors.lastname: Levin
mesh_terms: D000328:Adult; D017668:Age of Onset; D000588:Amines / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D019970:Cocaine-Related Disorders / Q000534:rehabilitation*; D015928:Cognitive Behavioral Therapy / Q000379:methods; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000534:rehabilitation*; D010879:Piperazines; D014230:Triazoles / Q000627:therapeutic use; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D018687:Antidepressive Agents, Second-Generation; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D014230:Triazoles; D016642:Bupropion; D005680:gamma-Aminobutyric Acid; C051752:nefazodone; D000077206:Gabapentin